Article

GB10, a best-in-class antibody fusion protein targeting VEGF/Ang-2, exhibits promising therapeutic efficacy for neovascular eye diseases

2024-11-18

Abstract excerpt

<title>Abstract</title> <p>Background In clinical practice, anti-vascular endothelial growth factor (VEGF) therapies have been successfully applied to patients with neovascular eye diseases. However, unmet clinical needs have not yet been fully addressed, as about 20% of patients do not response to anti-VEGF monotherapies, meanwhile, the high frequency of intravitreal (IVT) injections imposes a significant burde...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 391a62a8-5212-5f57-851b-011cc8cac7c2
DOI: 10.21203/rs.3.rs-5135499/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

GB10, a best-in-class antibody fusion protein targeting VEGF/Ang-2, exhibits promising therapeutic efficacy for neovascular eye diseasesDOI 10.21203/rs.3.rs-5135499/v1Read

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applicationsSemantic proximity Read

Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesSemantic proximity Read

Enhancing Anti-Angiogenic Therapy with Bevacizumab-Loaded Nanoflowers Through The Chorioallantoic Membrane AssaySemantic proximity Read

Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMDSemantic proximity Read

Clinical Pharmacology Perspective on Development of Adeno‐Associated Virus Vector‐Based Retina Gene TherapySemantic proximity Read

Clinical care and therapeutic practice of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and effectiveness of faricimab in treatment-naive patients in Germany - ZEUS research projectSemantic proximity Read

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in OphthalmologySemantic proximity Read

The 20th Anniversary of Pegaptanib (MacugenTM), the First Approved Aptamer Medicine: History, Recent Advances and Future Prospects of Aptamers in TherapySemantic proximity Read

Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degenerationSemantic proximity Read

Evaluation of Collagen-Derived peptide (EB-203) for Treating Wet Age-Related Macular DegenerationSemantic proximity Read

A novel vascular endothelial growth factor-trap KP-VR2 with enhanced ligand blockingSemantic proximity Read

Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.Semantic proximity Read